These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
559 related articles for article (PubMed ID: 30359792)
21. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer. Ishida M; Iwasaku M; Doi T; Ishikawa T; Tachibana Y; Sawada R; Ogura Y; Kawachi H; Katayama Y; Nishioka N; Morimoto K; Tokuda S; Yamada T; Takayama K Cancer Sci; 2024 May; 115(5):1656-1664. PubMed ID: 38450844 [TBL] [Abstract][Full Text] [Related]
22. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers. Marchal M; Leroy V; Behal H; Dansin E; Paris N; Bordier S; Humez S; Escande F; Gauvain C; Cortot AB Target Oncol; 2023 Nov; 18(6):927-939. PubMed ID: 37921939 [TBL] [Abstract][Full Text] [Related]
23. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. Tan AC; Itchins M; Khasraw M Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103 [TBL] [Abstract][Full Text] [Related]
24. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776 [TBL] [Abstract][Full Text] [Related]
25. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. Pisapia P; Iaccarino A; De Luca C; Acanfora G; Bellevicine C; Bianco R; Daniele B; Ciampi L; De Felice M; Fabozzi T; Formisano L; Giordano P; Gridelli C; Ianniello GP; Libroia A; Maione P; Nacchio M; Pagni F; Palmieri G; Pepe F; Russo G; Salatiello M; Santaniello A; Scamarcio R; Seminati D; Troia M; Troncone G; Vigliar E; Malapelle U Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955681 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations. Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960 [TBL] [Abstract][Full Text] [Related]
28. Somatic mutations and immune checkpoint biomarkers. Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374 [TBL] [Abstract][Full Text] [Related]
29. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Schneider F; Derrick V; Davison JM; Strollo D; Incharoen P; Dacic S Mod Pathol; 2016 Jul; 29(7):735-42. PubMed ID: 27080983 [TBL] [Abstract][Full Text] [Related]
31. Targeted therapeutic options in early and metastatic NSCLC-overview. Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928 [TBL] [Abstract][Full Text] [Related]
32. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities. Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064 [TBL] [Abstract][Full Text] [Related]
33. Predictive markers in lung cancer: a few hints for the practicing pathologist. Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911 [TBL] [Abstract][Full Text] [Related]
34. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. Chen LF; Chen XY; Yu XB Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383 [TBL] [Abstract][Full Text] [Related]
36. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. Kim JH; Kim HS; Kim BJ Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386 [TBL] [Abstract][Full Text] [Related]
37. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. Soo R; Mery L; Bardot A; Kanesvaran R; Keong TC; Pongnikorn D; Prasongsook N; Hutajulu SH; Irawan C; Manan AA; Thiagarajan M; Sripan P; Peters S; Storm H; Bray F; Stahel R ESMO Open; 2022 Oct; 7(5):100560. PubMed ID: 35988454 [TBL] [Abstract][Full Text] [Related]
38. Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases. Tan L; Hu Y; Tao Y; Wang B; Xiao J; Tang Z; Lu T; Tang H Thorac Cancer; 2018 Apr; 9(4):445-451. PubMed ID: 29473341 [TBL] [Abstract][Full Text] [Related]
39. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Shah AT; Blanchard I; Padda SK; Wakelee HA; Neal JW Clin Lung Cancer; 2024 Sep; 25(6):550-559. PubMed ID: 38987048 [TBL] [Abstract][Full Text] [Related]
40. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid). Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]